共 50 条
Exploration of the anti-hyperuricemia effect of TongFengTangSan (TFTS) by UPLC-Q-TOF/MS-based non-targeted metabonomics
被引:12
|作者:
Huang, Zhichao
[1
]
Zhang, Wugang
[1
,2
]
An, Qiong
[1
]
Lang, Yifan
[2
]
Liu, Ye
[2
]
Fan, Huifang
[2
]
Chen, Haifang
[1
]
机构:
[1] Jiangxi Univ Chinese Med, Key Lab Modern Preparat Tradit Chinese Med, Minist Educ, 1688 Meiling Rd, Nanchang 330004, Peoples R China
[2] Jiangxi Univ Tradit Chinese Med, State Key Lab Innovat Drug & Efficient Energy Savi, Nanchang 330006, Peoples R China
基金:
中国国家自然科学基金;
关键词:
TFTS;
Hyperuricemia;
Metabolomics;
Mechanism;
METABOLOMICS;
DISEASE;
UPDATE;
D O I:
10.1186/s13020-023-00716-w
中图分类号:
R [医药、卫生];
学科分类号:
10 ;
摘要:
BackgroundTongFengTangSan (TFTS) is a commonly used Tibetan prescription for gout treatment. Previously, TFTS (CF) was confirmed to have a significant uric acid-lowering effect. However, the anti-hyperuricemia mechanisms and the main active fractions remain unclear. The current study aimed to investigate the anti-hyperuricemia mechanism using metabolomics and confirm the active CF fraction.MethodsThe hyperuricemia model was established through intraperitoneal injection containing 100 mg/kg potassium oxonate and 150 mg/kg hypoxanthine by gavage. We used serum uric acid (sUA), creatinine (CRE), blood urea nitrogen (BUN), xanthine oxidase (XOD) activity, interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta) as indicators to evaluate the efficacy of CF and the four fractions (SX, CF30, CF60, and CF90). The anti-hyperuricemia mechanism of CF was considered through non-targeted metabolomics depending on the UPLC-Q-TOF-MS technology. Principle component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) helped explore the potential biomarkers in hyperuricemia. Moreover, the differential metabolites and metabolic pathways regulated by CF and four fractions were also assessed.ResultsCF revealed a significant anti-hyperuricemia effect by down-regulating the level of sUA, sCRE, sIL-1 beta, and XOD. SX, CF30, CF60, and CF90 differed in the anti-hyperuricemia effect. Only CF60 significantly lowered the sUA level among the four fractions, and it could be the main efficacy fraction of TFTS. Forty-three differential metabolites were identified in hyperuricemia rats from plasma and kidney. Pathway analysis demonstrated that seven pathways were disrupted among hyperuricemia rats. CF reversed 19 metabolites in hyperuricemia rats and exerted an anti-hyperuricemia effect by regulating purine metabolism. CF60 was the main active fraction of TFTS and exerted a similar effect of CF by regulating purine metabolism.ConclusionsCF and CF60 could exert an anti-hyperuricemia effect by regulating the abnormal purine metabolism because of hyperuricemia while improving intestinal and renal function. CF60 could be the main active fraction of TFTS.
引用
收藏
页数:19
相关论文